Eli Lilly Reports Exceptional 2025 Growth Driven by Mounjaro & Zepbound, Advances Key Pipeline Assets
Summary
Eli Lilly reported a 45% revenue increase and 95% diluted EPS growth in 2025, primarily fueled by strong demand for Mounjaro and Zepbound, while also advancing its pipeline with new approvals and significant manufacturing investments.
Key Events
-
Record Financial Performance
Eli Lilly reported a 45% increase in revenue to $65.18 billion and a 96% diluted EPS growth to $22.95 for the fiscal year ended December 31, 2025.
-
Blockbuster Product Sales
Revenue from Mounjaro nearly doubled to $22.97 billion, and Zepbound revenue surged 175% to $13.54 billion in 2025, with these two products collectively accounting for 56% of total revenues.
-
Significant Pipeline Advancements
Multiple regulatory approvals were secured for Tirzepatide (heart failure, pediatric diabetes), Donanemab (early Alzheimer's disease), Mirikizumab (Crohn's disease), and Imlunestrant (breast cancer). Orforglipron also received FDA Breakthrough Therapy designation.
-
Strategic Manufacturing Expansion
The company invested $7.84 billion in capital expenditures in 2025, a substantial increase from $5.06 billion in 2024, to expand global manufacturing capabilities and meet anticipated product demand.
Analysis
Eli Lilly's 2025 annual report highlights a period of remarkable financial and operational expansion. The company achieved substantial revenue and earnings per share growth, largely attributable to the blockbuster performance of its cardiometabolic health products, Mounjaro and Zepbound, which now constitute over half of total revenues. This growth is supported by strategic investments in manufacturing capacity and a robust pipeline with multiple regulatory approvals and breakthrough designations across key therapeutic areas like Alzheimer's and oncology. While the company faces ongoing challenges from drug pricing regulations, particularly the Inflation Reduction Act impacting key products, and various litigations, its aggressive R&D and manufacturing expansion efforts position it for continued leadership in the pharmaceutical sector.
At the time of this filing, LLY was trading at $1,046.86 on NYSE in the Life Sciences sector, with a market capitalization of approximately $989.7B. The 52-week trading range was $623.78 to $1,133.95. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.